Download PDF
Seminars in Neurosurgery 2001; 12(3): 289-294
DOI: 10.1055/s-2001-33619
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Is There a Role for Surgery for Microprolactinomas?

Michael Y. Wang, Martin H. Weiss
  • Department of Neurological Surgery, Keck School of Medicine, Los Angeles County General Hospital/University of Southern California, Los Angeles, California
Further Information

Publication History

Publication Date:
27 August 2002 (online)

    Permissions and Reprints

ABSTRACT

The neurosurgical and endocrinologic treatment of prolactinomas has undergone significant advances in the past three decades. Because of medical progress, we are now confronted with two safe, effective approaches for treating prolactinomas. Transsphenoidal surgery for microprolactinomas carries a 90% cure rate while incurring minimal risks, and offers the only opportunity for endocrinologic and oncologic cure. Alternatively, treatment with bromocriptine and other dopaminergic agents also results in effective chemical control in greater than 90% of cases but requires lifelong treatment. Pharmacologic control of microprolactinomas remains the mainstay of treatment, but surgical indications include patients intolerant of medical treatment, failing medical therapy, and desiring pregnancy. Young patients wishing to avoid lifelong medical treatment may also be operative candidates. In these situations. surgery is a vital adjunct in the management of prolactinoma-secreting microadenomas.

KEYWORDS

Prolactinoma - transsphenoidal surgery - bromocriptine - pituitary adenoma

REFERENCES

  • 1 Cushing H. The Pituitary Body and Its Disorders.  Philadelphia, PA: JB Lippincott 1912
    Google Scholar
  • 2 Thapar K, Laws E. Pituitary tumors. In: Kaye A, Laws E, eds. Brain Tumors Edinburgh, Scotland: Churchill Livingstone 1995 0: 759-773
    Google Scholar
  • 3 Costello R. Subclinical adenoma of the pituitary gland.  Am J Path . 1936;  12 205-216
    PubMedGoogle Scholar
  • 4 Kovacs K, Horvath H. Pathology of pituitary tumors.  Endocrinol Metab Clin . 1987;  16 529-551
    PubMedGoogle Scholar
  • 5 Parent D, Bebin J, Smith R. Incidental pituitary adenomas.  J Neurosurg . 1981;  54 228-230
    PubMedGoogle Scholar
  • 6 Evans W, Thorner M. Mechanisms for hypogonadism in hyperprolactinemia.  Semin Reprod Endocrinol . 1984;  2 9-22
    PubMedGoogle Scholar
  • 7 Weiss M. Pituitary tumor: an endocrinological and neurosurgical challenge.  Clin Neurosurg . 1992;  39 114-122
    PubMedGoogle Scholar
  • 8 Touraine P, Plu-Bureau G, Beji C, Mauvais-Jarvis P, Kuttenn F. Long-term follow-up of 246 hyperprolactinemic patients.  Acta Obstet Gynecol Scand . 2001;  80 162-168
    CrossrefPubMedGoogle Scholar
  • 9 Weiss M, Teal J, Gott P. Natural history of microprolactinomas: six-year follow-up.  Neurosurgery . 1983;  12 180-183
    PubMedGoogle Scholar
  • 10 Weiss M. Medical and surgical management of functional pituitary tumors.  Clin Neurosurg . 1981;  28 374-383
    PubMedGoogle Scholar
  • 11 Katz E, Schran H, Adashi E. Successful treatment of a prolactin-producing pituitary macroadenoma with intravaginal bromocriptine mesylate: a novel approach to intolerance of oral therapy.  Obstet Gynecol . 1989;  73 517-519
    PubMedGoogle Scholar
  • 12 Orrego J, Barkan A. Pituitary disorders: drug treatment options.  Drugs . 2000;  59 93-106
    PubMedGoogle Scholar
  • 13 Pinzone J, Katznelson L, Danila D, Pauler D, Miller C, Klibanski A. Primary medical therapy of micro- and macroprolactinomas in men.  J Clin Endocrinol Metab . 2000;  85 3053-3057
    CrossrefPubMedGoogle Scholar
  • 14 Webster J, Piscitelli G, Polli A. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea.  N Engl J Med . 1994;  331 904-909
    CrossrefPubMedGoogle Scholar
  • 15 Di Sarno A, Landi M, Marzullo P. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.  Clin Endocrinol . 2000;  53 53-60
    CrossrefPubMedGoogle Scholar
  • 16 Molitch M. Management of prolactinomas during pregnancy.  J Reprod Med . 1999;  44 S1121-S1126
    PubMedGoogle Scholar
  • 17 Jewelewicz R, Vande Wiele R. Clinical course and outcome of pregnancy in twenty-five patients with pituitary microadenomas.  Am J Obstet Gynecol . 1980;  136 339-343
    PubMedGoogle Scholar
  • 18 Vician L, Shupnik M, Gorski J. Effects of estrogen on primary ovine pituitary cell cultures: stimulation of prolactin secretion, synthesis and prolactin messenger ribonucleic acid levels.  Endocrinology . 1979;  104 736-743
    PubMedGoogle Scholar
  • 19 Molitch M. Medical treatment of prolactinomas.  Endocrinol Metab Clin North Am . 1999;  28 143-169
    CrossrefPubMedGoogle Scholar
  • 20 Little M, Shalet S, Beardwell C. Hypopituitarism following external radiotherapy for pituitary tumors in adults.  J Med . 1989;  70 145-160
    PubMedGoogle Scholar
  • 21 Pan L, Zhang N, Wang E, Wang B, Dai J, Cai P. Gamma knife radiosurgery as a primary treatment for prolactinomas.  J Neurosurg . 2000;  93 S10-S13
    PubMedGoogle Scholar
  • 22 Landolt A, Lomax N. Gamma knife radiosurgery for prolactinomas.  J Neurosurg . 2000;  93 S14-S18
    PubMedGoogle Scholar
  • 23 March C, Kletzky O, Davajan V. Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas.  Am J Obstet Gynecol . 1981;  139 835-844
    PubMedGoogle Scholar
  • 24 Shimon I, Hinton D, Weiss M, Melmed S. Prolactinomas express human heparin-binding secretory transforming gene (hst) protein product: marker of tumour invasiveness.  Clin Endocrinol . 1998;  48 23-29
    CrossrefPubMedGoogle Scholar
  • 25 Sakamoto H, Mori M, Taira M. Transforming gene from human stomach cancers and a noncancerous portion of stomach mucosa.  Proc Natl Acad Sci USA . 1986;  83 3997-4001
    PubMedGoogle Scholar
  • 26 Velcich A, Delli Bovi P, Mansukhani A, Ziff E, Basilico C. Expression of the K-fgf proto-oncogene is repressed during differentiation of F9 cells.  Oncogene Res . 1989;  5 31-37
    PubMedGoogle Scholar
  • 27 Adelaide J, Mattei M, Marics I. Chromosomal localization of the hst oncogene and its co-amplification with the int.2 oncogene in human melanoma.  Oncogene . 1988;  2 413-416
    PubMedGoogle Scholar
  • 28 Neal J, Weiss M. Management of prolactin-secreting pituitary adenomas.  West J Med . 1990;  153 546-547
    PubMedGoogle Scholar
  • 29 Weiss M. Treatment options in the management of prolactin-secreting pituitary tumors.  Clin Neurosurg . 1986;  33 547-552
    PubMedGoogle Scholar
  • 30 Ozgen T, Oruckaptan H, Ozcan O, Acikgoz B. Prolactin secreting pituitary adenomas: analysis of 429 surgically treated patients, effects of adjuvant treatment modalities and review of the literature.  Acta Neurochir . 1999;  141 1287-1294
    CrossrefPubMedGoogle Scholar
  • 31 Couldwell W, Weiss M. Defining postoperative values for successful resection of prolactinomas.  J Neurosurg . 1996;  85 990-991
    PubMedGoogle Scholar
  • 32 Ciric I, Ragin A, Baumgartner C. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience.  Neurosurgery . 1997;  40 225-237
    CrossrefPubMedGoogle Scholar
  • 33 Zacur H. Indications for surgery in the treatment of hyperprolactinemia.  J Reprod Med . 1999;  44 S1127-S1131
    PubMedGoogle Scholar
  • 34 Landolt A. Surgical treatment of pituitary prolactinomas: postoperative prolactin and fertility in seventy patients.  Fertil Steril . 1981;  35 620-625
    PubMedGoogle Scholar
  • 35 Weiss M, Wycoff R, Yadley R, Gott P, Feldon S. Bromocriptine treatment of prolactin-secreting tumors: surgical implications.  Neurosurgery . 1983;  12 640-642
    PubMedGoogle Scholar
  • 36 Pellegrini I, Rasolonjanahary R, Gunz G. Resistance to bromocriptine in prolactinomas.  J Clin Endocrinol Metab . 1989;  69 500-509
    CrossrefPubMedGoogle Scholar
      >